Cargando…

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies

Interleukin-15 (IL-15) monotherapy substantially increases the number and activity of natural killer (NK) cells and CD8(+) T cells but has not produced clinical responses. In a xenograft mouse model, IL-15 enhanced the NK cell–mediated antibody-dependent cell cytotoxicity (ADCC) of the anti-CD52 ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miljkovic, Milos D., Dubois, Sigrid P., Müller, Jürgen R., Bryant, Bonita, Ma, Elaine, Conlon, Kevin C., Waldmann, Thomas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Immunobiology and Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898617/ https://www.ncbi.nlm.nih.gov/pubmed/35475910 http://dx.doi.org/10.1182/bloodadvances.2021006440

Ejemplares similares

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
por: Berdel, Andrew F., et al.
Publicado: (2022)

Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function
por: Trikha, Prashant, et al.
Publicado: (2021)

Allelic variation of KIR and HLA tunes the cytolytic payload and determines functional hierarchy of NK cell repertoires
por: Philippon, Camille, et al.
Publicado: (2023)

Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
por: Vogiatzi, Fotini, et al.
Publicado: (2022)

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
por: Daly, John, et al.
Publicado: (2022)

NK cells CD56(bright) and CD56(dim) subset cytokine loss and exhaustion is associated with impaired survival in myeloma
por: Seymour, Frances, et al.
Publicado: (2022)

GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post–allo-HSCT
por: Wang, Dongyao, et al.
Publicado: (2022)

Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease
por: Kinoshita, Hannah, et al.
Publicado: (2022)

Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma
por: Watanabe, Keisuke, et al.
Publicado: (2023)

Dangerous B-cell clones
por: Greinacher, Andreas, et al.
Publicado: (2022)

T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome
por: Kumar, Deepak, et al.
Publicado: (2022)

Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant
por: Jiang, Wei, et al.
Publicado: (2022)

HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
por: Bourbon, Estelle, et al.
Publicado: (2022)

Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy
por: Little, Jessica S., et al.
Publicado: (2023)

Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8(+) T cells into B-cell follicles during HIV-1 infection
por: Ogunshola, Funsho J., et al.
Publicado: (2022)

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
por: Lee, Jong Bok, et al.
Publicado: (2021)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia
por: Montironi, Chiara, et al.
Publicado: (2023)

Complementary HLH susceptibility factors converge on CD8 T-cell hyperactivation
por: Landy, Emily, et al.
Publicado: (2023)

Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL
por: Diorio, Caroline, et al.
Publicado: (2022)

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
por: Lamble, Adam J., et al.
Publicado: (2022)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19
por: Osman, Mohammed, et al.
Publicado: (2020)

Cytokine-induced natural killer cell training is dependent on cellular metabolism and is defective in obesity
por: Kedia-Mehta, Nidhi, et al.
Publicado: (2021)

Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment
por: Panetti, Silvia, et al.
Publicado: (2022)

TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones
por: Shaw, Lauren C., et al.
Publicado: (2022)

Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy
por: Jalota, Akansha, et al.
Publicado: (2022)

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
por: Philipp, Nora, et al.
Publicado: (2022)

Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia
por: Shahid, Sanam, et al.
Publicado: (2023)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

4-1BBL–containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells
por: Swatler, Julian, et al.
Publicado: (2022)

Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
por: Mouhieddine, Tarek H., et al.
Publicado: (2022)

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
por: Juluri, Krishna R., et al.
Publicado: (2022)

Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors
por: Tamaki, Masaharu, et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells
por: Michelozzi, Ilaria M., et al.
Publicado: (2022)

Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma
por: Dean, Erin A., et al.
Publicado: (2023)

Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation
por: Kim, Alexander B., et al.
Publicado: (2023)

Activated protein C modulates T-cell metabolism and epigenetic FOXP3 induction via α-ketoglutarate
por: Gupta, Dheerendra, et al.
Publicado: (2023)

Complement and platelets: prothrombotic cell activation requires membrane attack complex–induced release of danger signals
por: Mannes, Marco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_49a4ru1td4lov35igrp6hqsbrf